New treatments for erectile dysfunction
DOI:
https://doi.org/10.15277/bjdvd.2015.012Abstract
Erectile dysfunction (ED) is common in men with diabetes and is associated with microvascular disease, maladaptation to chronic illness, poor quality of life, and increased levels of diabetes-specific health distress. Traditionally, most diabetologists were poor at asking about ED and patients themselves are not always forthcoming with information, given the embarrassing nature of the disease. However, times are changing and the inclusion of screening for ED in Quality and Outcomes Framework and current general practice templates emphasises its current importance. Licensed treatments have been limited in their application towards the provision of symptomatic relief and are offset by adverse effects, intolerance, limited effectiveness and contraindications in the presence of co-existent cardiovascular disease. This review critically considers the utility of novel treatments for ED in diabetes that have been developed to overcome these barriers.References
McCulloch DK, Campbell IW, Wu FC, et al. The prevalence of diabetic impotence. Diabetologia 1980;18:279-83. http://dx.doi.org/10.1007/BF00251005
Jamieson F, Chalmers J, Duncan C, et al. Erectile dysfunction in type 1 diabetic males. Br J Diabetes Vasc Dis 2008;8:232-34. http://dx.doi.org/10.1177/1474651408094536
De Berardis G, Franciosi M, Belfiglio M, et al. Erectile dysfunction and quality of life in type 2 diabetic patients: a serious problem too often overlooked. Diabetes Care 2002;25:284-91. http://dx.doi.org/10.2337/diacare.25.2.284
Grant P, Lipscomb D. How often do we ask about erectile dysfunction in the diabetes review clinic? Development of a neuropathy screening tool. Acta Diabetol 2009;46:285-90. http://dx.doi.org/10.1007/s00592-008-0084-1
Eardley I. Pathophysiology of erectile dysfunction. Br J Diabetes Vasc Dis 2002;2:272-6. http://dx.doi.org/10.1177/14746514020020040701
Rosen RC, Cappelleri JC, Gendrano N. The International Index of Erectile Function (IEFF): a state-of-the-science review. Int J Impotence Res 2002;14:226-44. http://dx.doi.org/10.1038/sj.ijir.3900857
Cappelleri JC, Rosen RC. The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience. Int J Impotence Res 2005;17:307-19. http://dx.doi.org/10.1038/sj.ijir.3901327
Kalsi J, Kell P. Update on the oral treatments for male erectile dysfunction. Eur Acad Dermatol Venereol 2004;18:267-74. http://dx.doi.org/10.1111/j.1468-3083.2004.00885.x
Porst H, Hell-Momeni K, Buttner H. Chronic PDE-5 inhibition in patients with erectile dysfunction – a treatment approach using Tadalafil once-daily. Exp Opin Pharmacother 2012;13:1481-94. http://dx.doi.org/10.1517/14656566.2012.693162
Muse® alprostadil urethral suppository. US Summary of Product Characteristics (Meda Pharmaceuticals). Available at http://www.muserx.com/hcp/global/full-prescribing-information.aspx (accessed January 2015).
Padma-Nathan H, Yeager JL. An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. Urology 2006;68:386-91. http://dx.doi.org/10.1016/j.urology.2006.02.027
Rooney M, Pfister W, Mahoney M, et al. Long-term multi-centre study of the safety and efficacy of topical Alprostadil cream in male patients with erectile dysfunction. J Sex Med 2009;6:520-34. http://dx.doi.org/10.1111/j.1743-6109.2008.01118.x
Hanchanale V, Eardley I. Alprostadil for the treatment of impotence. Exp Opin Pharmacother 2014;15:421-8. http://dx.doi.org/10.1517/14656566.2014.873789
Zhao C, Kim S, Yang D, et al. Efficacy and safety of Avanafil for treating erectile dysfunction: results of a multi-centre, randomised, double-blind, placebo-controlled trial. Br J Urol Int 2012;110:1801-06. http://dx.doi.org/10.1111/j.1464-410X.2012.11095.x
Glina S, Fonseca GN, Bertero EB, et al. Efficacy and tolerability of Lodenafil carbonate for oral therapy of erectile dysfunction: a phase III clinical trial. J Sex Med 2010;7:1928-36. http://dx.doi.org/10.1111/j.1743-6109.2010.01711.x
Du W, Li J, Fan N, et al. Efficacy and safety of mirodenafil for patients with erectile dysfunction: a meta-analysis of three multicenter, randomized, double-blind, placebo-controlled clinical trials. Aging Male 2014;17:107-11. http://dx.doi.org/10.3109/13685538.2013.858114
Ding H, Du W, Wang H, et al. Efficacy and safety of Udenafil for erectile dysfunction: a meta-analysis of randomised controlled trials. Urology 2012;80:134-9. http://dx.doi.org/10.1016/j.urology.2012.02.014
Fraga-Silva RA, Montecucco F, Mach F, et al. Pathophysiological role of the renin-angiotensin system on erectile function. Eur J Clin Invest 2013;43:978-85. http://dx.doi.org/10.1111/eci.12117
Fraga-Silva RA, Costa-Fraga FP, Savergnini SQ, et al. An oral formulation of angiotensin-(1-7) reverses corpus cavernosum damages induced by hypercholesterolemia. J Sex Med 2013;10:2430-42. http://dx.doi.org/10.1111/jsm.12262
Fogari R, Zoppi A, Poletti L, et al. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 2001;14:27-31. http://dx.doi.org/10.1016/S0895-7061(00)01214-0
Vardi Y, Gruenwald I, Gedalia U, et al. Evaluation of penile revascularisation for erectile dysfunction: a 10-year follow-up. Int J Impotence Res 2004;16:181-6. http://dx.doi.org/10.1038/sj.ijir.3901120
Blute M, Hakimian P, Kashanian J, et al. Erectile dysfunction and testosterone deficiency. Front Horm Res 2009;37:108-22. http://dx.doi.org/10.1159/000176048
Hakim L, Van der Aa F, Bivalacqua TJ, et al. Emerging tools for erectile dysfunction: a role for regenerative medicine. Nat Rev Urol 2012;9:520-36. http://dx.doi.org/10.1038/nrurol.2012.143
Published
Issue
Section
License
Publish & Transfer of Copyright Agreement
For the mutual benefit and protection of the Author and the Journal Owner/Publisher it is necessary that the Author provides formal written Consent to Publish and Transfer of Copyright before publication of the Work.
